Anderson Center for Hair · Workload Analysis
Surgical Workload & Practice Performance
Executive Summary · June 2024 – May 2026 · 24 Months
A What the data says
Production rose from 678,350 grafts to 786,965 — outpacing the +12.5% rise in case count (328 → 369). The operations are bigger, with average case size climbing from ~2,068 to ~2,133 grafts.
Dr. Wetzel's caseload grew +32% (165 → 217) while Dr. Anderson held a deliberate cadence (163 → 152). The single most important workforce signal in the data.
FUE (WAW) rose from under half of cases to a clear majority in Year 2. The full-window split is 51% / 49%, but the trajectory is decisively toward FUE.
Both annual cycles show the same shape: a strong Q4 peak (the biggest month on record was 108,100 grafts in Dec 2025) and a late-summer trough.
PRP, exosomes, PRF and combinations run at about 1.6 for every surgical case, steady year over year, with the mix evolving toward exosome-plus-PRF. Exosomes attach to roughly one in six surgeries.
Operating days held a sustainable rhythm — Wetzel ~13/month, Anderson ~10/month. Non-operating time is overwhelmingly purposeful: clinic, regenerative work, admin, teaching and conference travel.
B Production over time
Monthly graft volume with a three-month rolling average. May 2026 is shown partial through the 22nd, with a dotted projection to its expected full-month value.
Year 1 = Jun 2024–May 2025; Year 2 = Jun 2025–May 2026. June 2024 is the start of the data window, not the practice, so it is not a baseline "launch" figure.
C The two surgeons
The clearest structural story is how the two surgeons' roles diverged in Year 2. Dr. Wetzel became the primary surgical engine, growing his share to roughly two-thirds of all cases, while Dr. Anderson maintained a steady, lighter surgical cadence.
This is a balance to monitor, not a problem to fix. Anderson's protected non-operating time covers business leadership, teaching, and conference presence — part of how the practice operates by design.
How surgical days are actually spent
Operating share shown in white. "Available, unbooked" (genuinely idle capacity) is the red band — small throughout. Conference / teaching / admin time is shown distinctly to make clear it is purposeful, not lost.
D Technique & case size
Technique mix shift
Case size concentration
| Graft range | Cases | Share |
|---|---|---|
| Under 1,000 | 19 | 3% |
| 1,000–1,499 | 43 | 6% |
| 1,500–1,999 | 118 | 17% |
| 2,000–2,499 | 345 | 49% |
| 2,500–2,999 | 170 | 24% |
| 3,000+ | 2 | <1% |
Nearly three-quarters of cases fall in the 2,000–3,000 graft range — a tightly concentrated core offering. Size tier (billing category) is tracked separately from graft volume; the XLarge tier began Jan 2025.
E Two service lines
Surgery and the regenerative line move as two distinct streams. Surgery carries the seasonal swing; the regenerative line is steadier month to month, giving a more consistent baseline of activity between surgical peaks.
Regenerative mix
| Treatment | Yr 1 | Yr 2 |
|---|---|---|
| PRP | 319 | 336 |
| Exosomes (standalone) | 148 | 62 |
| Exosomes + PRF | 34 | 101 |
| PRF (standalone) | 34 | 32 |
| Exosomes + PRP | 3 | 17 |
| Exo Booster + PRF | 2 | 2 |
| Total | 540 | 550 |
What's shifting
PRP remains the steady backbone. The notable move is within exosome delivery: standalone exosome treatments gave way to exosome-plus-PRF combinations (34 → 101) in Year 2 — a product-mix evolution rather than a volume change.
Each regenerative type will map to its own price input in the dashboard, so the surgery-vs-regenerative revenue comparison can be modeled precisely once pricing is entered.
F Seasonality
Averaged across both annual cycles, the shape is consistent: the practice builds through autumn to a December peak, then runs lighter through late summer. With only two complete cycles this is a pattern to note rather than a hard forecast, but its repetition across both years gives it real weight.